Quarterly report pursuant to Section 13 or 15(d)

4. COMMON STOCK TRANSACTIONS (Details Narrative)

4. COMMON STOCK TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Apr. 30, 2019
Shelf Offering [Member]
Stock issued new, shares	66,700,000	66,200,000
Proceeds from sale of equity	$ 558,000	$ 1,400,000
Common Stock [Member] \| Three Consultants [Member] \| 2017 Consulting Agreements [Member]
Stock based compensation expense	$ 0	$ 45,800
Unvested shares	0	500,000
Common Stock [Member] \| Officers [Member] \| 2018 Compensation Agreement [Member]
Stock based compensation expense	$ 0	$ 92,070
Unvested shares	0	2,750,000
Common Stock [Member] \| Officers [Member] \| 2019 Compensation Agreement [Member]
Stock issued for compensation, shares			6,600,000
Stock based compensation expense	$ 104,726
Unvested shares	2,750,000
Common Stock [Member] \| Four Independent Directors [Member] \| 2018 Compensation Agreement [Member]
Stock issued for compensation, shares	2,000,000
Stock based compensation expense	$ 13,804
Common Stock [Member] \| Consultant [Member]
Stock issued for compensation, shares		1,200,000
Stock based compensation expense	$ 12,816
Unvested shares	0
Common Stock [Member] \| Two Consultants [Member] \| 2019 Compensation Agreement [Member]
Stock issued for compensation, shares			2,500,000
Stock based compensation expense	$ 7,209
Unvested shares	83,333
Common Stock [Member] \| A Consultant [Member] \| 2019 Compensation Agreement [Member]
Stock based compensation expense	$ 3,306
Unvested shares	500,000
Common Stock [Member] \| Three Directors [Member] \| DLA [Member]
Stock issued for compensation, shares	1,500,000
Stock based compensation expense	$ 11,642
Common Stock [Member] \| Consultant [Member] \| Medical and Scientific Advisory Board [Member]
Stock issued for compensation, shares	2,000,000
Stock based compensation expense	$ 7,150
Unvested shares	0